Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin.

Blood Adv · 2024 · PMC11652759 · PMID 39348668

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

20 The data revealed that FLT3 -ITD MRD was a highly significant risk factor for relapse and OS and even outperformed known risk factors, such as NPM1 mutational status and FLT3 -ITD AR.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.